- Announced January 15, 2026 by Boston Scientific and Penumbra. The merger agreement is dated January 14, 2026, and the board of each company approved it.
- Each Penumbra share can be exchanged, at the holder’s election, for $374.00 in cash or 3.8721 Boston Scientific shares, subject to proration (Section 2.01). The announcement valued the 3.8721 shares at $374 using Boston Scientific’s volume weighted average price over the 10 trading days as of January 13, 2026, and put the enterprise value at approximately $14.5 billion. The proxy statement says the exchange ratio is fixed and “will not be adjusted for stock price changes.”
- Proration sets the overall mix. Cash goes to 73.26% of the Penumbra shares converted in the merger and stock to 26.74% (Section 2.02(a)). If cash elections exceed 73.26%, shares with no election get stock and every cash election is cut back by the same fraction, with the rest paid in stock. If cash elections fall short, shares with no election move to cash first, then stock elections, pro rata (Section 2.02(b)).
- The election form is mailed at least 20 business days before the expected election deadline, to holders of record as of five business days before the mailing date, and you can elect cash for some shares and stock for others (Section 2.03(a) and (c)). Shares without a properly completed election form received by the deadline count as shares with no election (Section 2.03(d)).
- The election deadline is 5 p.m. New York City time on the date five business days before Boston Scientific’s good faith estimate of the closing date, unless the companies agree on another time and date. Penumbra and Boston Scientific will announce the deadline by press release at least five business days before it. If the closing date is delayed, the deadline is delayed too, and the companies will promptly announce the delay and, once set, the new deadline (Section 2.03(d)).
- You can change or revoke an election by written notice the exchange agent receives before the deadline (Section 2.03(e)). The proxy statement says you “will not be able to transfer” the shares covered by your election unless you revoke it before the deadline.
- Penumbra stockholders approved the merger at a special meeting on May 6, 2026, with 28,564,786 shares voting for, 85,334 against and 15,813 abstaining.
- The conditions left after the vote include the end of the Hart-Scott-Rodino waiting period and the other government approvals listed in a schedule to the agreement (Section 7.01(c)). The companies filed under the HSR Act on February 13, 2026, and each received a request for additional information, known as a Second Request, from the FTC on March 16, 2026. The proxy statement said the merger was expected to be subject to clearance or approval under the competition laws of the European Union and the competition and foreign investment laws of certain other countries.
- At announcement the companies said the transaction was expected to be completed in 2026. Penumbra’s Form 10-Q dated October 29, 2026 said the merger was expected to close in early 2027. Boston Scientific’s Form 10-Q dated November 2, 2026 said the companies were responding to the Second Request and the transaction was expected to be completed in early 2027, subject to closing conditions including regulatory clearances.
- If the merger has not taken effect by January 14, 2027, the agreement can generally be terminated. Either company may extend that date by written notice in three month steps, up to January 14, 2028, if on the scheduled end date the regulatory conditions are still unmet and the other conditions have been met or waived, or could be met if closing took place that day (Section 8.01(b)). Closing takes place on the fifth business day after the last condition is met or waived, unless the companies agree in writing on another date (Section 1.02).
- Options, vested or unvested, with an exercise price below the equity award value are cancelled at close for $274.00 in cash plus 1.0353 Boston Scientific shares for each share, with the exercise price and tax withholding taken from the cash first and then from the shares. Options at or above that value are cancelled with no payment (Section 2.06(a) and (b)). The equity award value is $274.00 plus 1.0353 times the average of Boston Scientific’s daily volume weighted average prices on the NYSE over the 10 consecutive trading days ending two trading days before the closing date (Section 9.03).
- Every RSU still outstanding at close that was granted before January 1, 2026 vests at close. So do RSUs granted for a performance period that ended before that date (other than sales incentive plan awards), RSUs vested but not yet settled, RSUs that vest in full at closing under their own terms, and RSUs held by directors who are not employees or by specified officers. Each is paid $274.00 in cash plus 1.0353 Boston Scientific shares per share, with tax withholding taken from the cash first (Section 2.06(c)).
- Cash and shares for options and for the RSUs that vest at close are due as promptly as practicable after close and no later than 30 calendar days after it (Section 2.06(a) and (c)). For those RSUs, where paying on that schedule would cause a Section 409A penalty tax, payment comes on the earliest date that avoids it (Section 2.06(c)).
- Other RSUs, including PSUs and sales incentive plan awards that are not on that list, become Boston Scientific RSUs. Performance conditions for periods not complete at close are reasonably assessed on actual performance through the time the merger takes effect. Each converted RSU covers your Penumbra RSU shares times 1.0353, plus your Penumbra RSU shares times $274.00 divided by that 10 trading day Boston Scientific average price, each rounded down. It keeps the vesting terms set out in Penumbra’s disclosure schedule to the agreement, which was not filed, the other terms of the award agreement, and any terms that take effect at closing under the award’s own terms (Section 2.06(d) and Section 9.03).
- The proxy statement said the ESPP would be frozen and suspended at the end of the offering period in progress as of January 15, 2026, with no new participants and no changes to elections or contributions. The ESPP ends just before the merger takes effect (Section 2.06(e)). Penumbra’s Form 10-K for 2025 says each offering begins on May 20 or November 20 and ends on the following November 19 or May 19.
- In the merger agreement, Boston Scientific agreed with Penumbra that for one year after close it would provide continuing employees base pay no less favorable than before close, incentive opportunities no less favorable in the aggregate than those it provides to its similarly situated employees (through December 31, 2027 if that comes first), and benefits, including severance but not any employee stock purchase plan, substantially comparable in the aggregate to Penumbra’s before close or Boston Scientific’s for similarly situated employees (Section 6.05(a)). Section 6.05(d) says nothing in the agreement is intended to create third party beneficiary rights for any employee, which generally means employees can’t enforce these terms themselves. It also says nothing in the agreement creates any right to continued employment or service.
- In an employee Q&A filed with the SEC on January 15, 2026, Penumbra said unvested RSUs “will generally vest upon the acquisition closing” and be exchanged for a mix of cash and Boston Scientific stock, and that employees with equity awards would get more details closer to close. The merger agreement’s list in Section 2.06(c) sets out which RSUs vest at close, and RSUs not on that list become Boston Scientific RSUs instead (Section 2.06(d)).
Sources. Boston Scientific and Penumbra joint press release, January 15, 2026, Boston Scientific’s Form 8-K and the merger agreement dated January 14, 2026, filed as Exhibit 2.1, Penumbra’s employee Q&A filed with the SEC on January 15, 2026, the proxy statement/prospectus dated April 1, 2026, Penumbra’s Form 8-K on the May 6, 2026 vote, Penumbra’s Form 10-K for 2025, and the Forms 10-Q for the quarter ended September 30, 2026 of Penumbra and Boston Scientific. BFA Wealth Management isn’t affiliated with Boston Scientific or Penumbra. The terms and dates above come from the announcement and filings named here, as of the date the facts were checked. They can change before close, so confirm the treatment of your own awards with HR before you act.
